Abbott Laboratories

Company: Abbott Laboratories
Based: Abbott Park, IL
Themes: Company-wide

Restructuring has become a near-permanent reality for most Big Pharma companies, and Abbott ($ABT) is no exception. It started in 2011 with plans to lay off 1,900 workers, and exactly a year later it came back for 700 more. Then, just days ago, Abbott added 550 more layoffs in its devices, nutrition, diagnostics and established pharmaceuticals units.

The diversified company had plenty of places to cut at the beginning of this year. But it didn't spare the pharma side of the business, which is being spun out as an independent company at the end of this year. About 200 jobs were slated for elimination in the diagnostics business, while 200 more would be canned in pharma manufacturing. But most of the layoffs were centered on Abbott's production of heart stents and diagnostics, after a drop-off in stent orders.

For the most recent round of layoffs, Abbott is taking a $478 million charge against earnings.

For more:
Special Report:
Abbott Laboratories - Top 10 pharma layoffs of 2011
Abbott's round of 700 layoffs doesn't spare pharma
Abbott's drug sales tick upward as AbbVie spinoff looms
Izvestia: Abbott engineers Russian vaccines buyout
 

Abbott Laboratories
Read more on

Suggested Articles

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.